## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%); PEG 2.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook**
- Source: Yahoo Finance | 20251228T021700 | Somewhat-Bullish | Relevance: 100%
- Zoetis Inc. (NYSE: ZTS) is included in Morgan Stanley’s 2026 Healthcare Playbook and is among 15 dividend stocks with low payout ratios and strong upside potential. Morgan Stanley lowered its price target for ZTS to $160 from $175 but maintained an "Overweight" rating, citing attractive opportunities in healthcare technology and providers for 2026. The company recently received Health Canada approval for Portela™ (relfovetmab injection) for feline osteoarthritis pain, with commercial launches expected in Canada and the EU in 2026.

**2. Vertex Pharmaceuticals (NASDAQ:VRTX) Nasdaq index Sustains Scientific Depth**
- Source: Kalkine Media | 20251230T080948 | Somewhat-Bullish | Relevance: 62%
- Vertex Pharmaceuticals (NASDAQ:VRTX) continues to be a prominent player in the global biotechnology sector, with a focus on research-driven therapies for serious diseases such as cystic fibrosis. The company's ongoing scientific depth and activity keep it visible within the Nasdaq index. To access the full article, readers are prompted to log in, create an account, or fill out a form.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 14.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.37 elevated, pricing in significant growth expectations. Forward P/E 18.6x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.37 |
| Forward P/E | 18.6 |
| Current P/E | 19.9 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.86x), long-term trend not supportive. MACD histogram positive (1.10), confirming momentum. RSI neutral at 57. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.36% (CS: 89) | Neutral |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | 1.10 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 0.856x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $126.42
- **Stop Loss:** $120.88 (4.4% risk)
- **Target:** $131.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $30,087.96
- **Portfolio %:** 30.09%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*